Dr Amanda Wooding Dr Amanda Wooding Deputy Head of Ventures

Amanda is Deputy Head of Ventures team at Cambridge Enterprise.

Since joining Cambridge Enterprise she has worked with both the Technology Transfer and Ventures teams to build and support early stage companies who are accessing University technology. Amanda has spun out six new companies and worked on several follow-on funding rounds and exits.

She currently sits on the boards of PredictImmune Limited and Kalium Health Limited and previously served on the board of Sphere Fluidics Limited for six years. She has considerable experience in all stages of the investment process from deal sourcing to due diligence, deal negotiation, investment management and beyond.

Outside of Cambridge Enterprise, Amanda is Deputy Chair of the BBSRC Follow on Fund Committee.

Previously Amanda worked for Acambis as the UK Director of Business Development where she notably secured a Phase III out licensing agreement with Sanofi Pasteur and managed the sale of a business unit to Crucell. While working for the Wellcome Trust in a forerunner of the Innovations team, she served as the Wellcome Trust observer to the board for three start-up biotechnology companies.

Amanda has a PhD in molecular endocrinology (University of Cambridge) and enjoyed post-doctoral research positions both at Cambridge and in industry.

Amanda joined Cambridge Enterprise Life Sciences Technology Transfer in January 2009, became Deputy Head of Life Sciences in 2012. She joined the Ventures team in 2021 as an Investment Director focusing on spin-out opportunities emerging from the life sciences and moved to her current role in 2023.